A meta-analysis looked at benzodiazepine receptor positive allosteric modulators for people with COPD and insomnia. These patients often struggle with poor sleep and breathing issues. The study combined data from multiple sources to see how the drug worked compared to a placebo.
The drug significantly improved total sleep time, reduced the number of times people woke up, and increased sleep efficiency. These short-term benefits were clear and statistically significant. However, the analysis also tracked serious health outcomes over the long term.
Long-term use of the drug was linked to higher risks. People taking it had more emergency department visits, more outpatient consultations, and more hospitalizations for COPD flare-ups. There was also a slight reduction in oxygen levels during sleep and a potential increase in all-cause mortality. The data suggests that while sleep improves quickly, the long-term dangers may outweigh the benefits for some patients.